ArticleEmerging infectious diseases2019
Rare Detection of Bordetella pertussis Pertactin-Deficient Strains in Argentina.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pertactin deficiency ofHuman vaccines & immunotherapeutics · 2024Pooled it
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- CD4+ T-cell immunity toDiscover immunity · 2026Review
- Resurgence of pertussis: Epidemiological trends, contributing factors, challenges, and recommendations for vaccination and surveillance.Human vaccines & immunotherapeutics · 2025Review
- Vaccine antigen-based genotyping ofMicrobiology spectrum · 2025Article
- Harnessing outer membrane vesicles derived fromFrontiers in immunology · 2025Article
- Molecular characterization and antimicrobial susceptibility for 62 isolates ofFrontiers in microbiology · 2024Article
- Genomic characterization ofMicrobial genomics · 2023Article
- Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity.Vaccines · 2022Review
- Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.Emerging infectious diseases · 2022Article
- Bbvac: A Live Vaccine Candidate That Provides Long-Lasting Anamnestic and Th17-Mediated Immunity against the Three ClassicalmSphere · 2022Article
- A Cross-Sectional Study Revealing the Emergence of Erythromycin-ResistantFrontiers in microbiology · 2022Article
- Can vaccines control bacterial virulence and pathogenicity?Evolution, medicine, and public health · 2022Review
- Easy identification of insertion sequence mobilization events in related bacterial strains with ISCompare.G3 (Bethesda, Md.) · 2021Article
- Prevalence and characterization of pertactin deficientVaccine: X · 2021Article
- Isolate-Based Surveillance of Bordetella pertussis, Austria, 2018-2020.Emerging infectious diseases · 2021Article
- Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.Frontiers in immunology · 2021Article
- Characterisation ofEpidemiology and infection · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis resurgence had been attributed to waning vaccine immunity and Bordetella pertussis adaptation to escape vaccine-induced immunity. Circulating bacteria differ genotypically from strains used in production of pertussis vaccine. Pertactin-deficient strains are highly prevalent in countries that use acellular vaccine (aP), suggesting strong aP-imposed selection of circulating bacteria. To corroborate this hypothesis, systematic studies on pertactin prevalence of infection in countries using whole-cell vaccine are needed. We provide pertussis epidemiologic data and molecular characterization of B. pertussis isolates from Buenos Aires, Argentina, during 2000-2017. This area used primary vaccination with whole-cell vaccine. Since 2002, pertussis case incidences increased at regular 4-year outbreaks; most cases were in infants <1 year of age. Of the B. pertussis isolates analyzed, 90.6% (317/350) contained the ptxP3-ptxA1-prn2-fim3-2 allelic profile. Immunoblotting and sequencing techniques detected only the 2 pertactin-deficient isolates. The low prevalence of pertactin-deficient strains in Argentina suggests that loss of pertactin gene expression might be driven by aP vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.